<table>
<thead>
<tr>
<th>Compound</th>
<th>Concentration (µM)</th>
<th>% Viability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nilotinib:KNS-81-FD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nilotinib:KU812</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nilotinib:KURAMOCHI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nilotinib:KYSE-410</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nilotinib:KYSE-520</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nilotinib:L-363</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nilotinib:L-428</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nilotinib:LCLC-103H</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nilotinib:LP-1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nilotinib:LS-123</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nilotinib:LS-513</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nilotinib:LU-99A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Concentration (μM) % Viability

CCLE  GDSC

PHA−665752:DM1S−114

PHA−665752:DOHH−2

PHA−665752:EB2

PHA−665752:EM−2

PHA−665752:GB−1

PHA−665752:GI−1

PHA−665752:HH

PHA−665752:HT

PHA−665752:HT−144

PHA−665752:HH
Concentration (μM) % Viability

CCLE
GDSC
TAE684:NCI−H1581
Concentration (µM)
% Viability
0.01
0.1
1
10
0
50
100
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
CCLE
GDSC
TAE684:NCI−H1648
Concentration (µM)
% Viability
0.01
0.1
1
10
0
50
100
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
CCLE
GDSC
TAE684:NCI−H1666
Concentration (µM)
% Viability
0.01
0.1
1
10
0
50
100
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
CCLE
GDSC
TAE684:NCI−H1694
Concentration (µM)
% Viability
0.01
0.1
1
10
0
50
100
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
CCLE
GDSC
TAE684:NCI−H1975
Concentration (µM)
% Viability
0.01
0.1
1
10
0
50
100
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
CCLE
GDSC
TAE684:NCI−H226
Concentration (µM)
% Viability
0.01
0.1
1
10
0
50
100
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
CCLE
GDSC
TAE684:NCI−H23
Concentration (µM)
% Viability
0.01
0.1
1
10
0
50
100
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
CCLE
GDSC
TAE684:ONS−76
Concentration (µM)
% Viability
0.01
0.1
1
10
0
50
100
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
CCLE
GDSC
TAE684:OPM−2
Concentration (µM)
% Viability
0.01
0.1
1
10
0
50
100
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
CCLE
GDSC
TAE684:OVCAR−4
Concentration (µM)
% Viability
0.01
0.1
1
10
0
50
100
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
CCLE
GDSC